In contrast, there might be fewer or no effects of PMS2 germline pathogenic variants because the cancer itself did not exhibit MSI-H or MMR deficiency in CGP analysis and MMR immunohistochemistry. This evidence concerns the gene MRC1 and mismatch repair cancer syndrome 1.